scispace - formally typeset
L

Laura M. Shelton

Researcher at Boston College

Publications -  27
Citations -  2229

Laura M. Shelton is an academic researcher from Boston College. The author has contributed to research in topics: Cancer & Glutamine. The author has an hindex of 18, co-authored 23 publications receiving 1880 citations.

Papers
More filters
Journal ArticleDOI

Cancer as a metabolic disease.

TL;DR: Evidence is reviewed supporting a general hypothesis that genomic instability and essentially all hallmarks of cancer, including aerobic glycolysis (Warburg effect), can be linked to impaired mitochondrial function and energy metabolism.
Journal ArticleDOI

SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance

TL;DR: A key role is identified for serine and glycine metabolism in the survival of brain cancer cells within the ischaemic zones of gliomas and SHMT2 activity limits that of pyruvate kinase and reduces oxygen consumption, eliciting a metabolic state that confers a profound survival advantage to cells in poorly vascularized tumour regions.
Journal ArticleDOI

Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells.

TL;DR: A competitive and partially redundant relationship between transaminases and GLUD is described, and they reveal how coupling of glutamate-derived carbon and nitrogen metabolism can be regulated to support cell proliferation.
Journal ArticleDOI

PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis

TL;DR: A metabolic adaptation that is required for hypoxia-induced BCSC enrichment and metastasis is reported, highlighting a role for PHGDH in the formation of secondary cancers and potential implications for therapeutic targeting of advanced cancers.
Journal ArticleDOI

Metabolic management of brain cancer.

TL;DR: This work proposes an alternative approach to brain cancer management that exploits the metabolic flexibility of normal cells at the expense of the genetically defective and metabolically challenged tumor cells.